ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

New Research: Side Effect of GLP1

Susan Brian

What Every Dermatologist Should Know About Emergency Contraception

American Acne and Rosacea Society (AARS)

A. Zaenglein, S. K. Horvath

Obesity: A Serious Cardiovascular Risk Factor? A Review of GLP-1 Rec…

Scripps Health

L. Vincent

An Introduction to Tirzepatide for Weightloss

Susan Brian

Predictors of Poor Response to Semaglutide for Weight Management

Ploutarchos Tzoulis

Etiology of Obesity

Beverly Tchang

The Cardiometabolic Syndrome: A New Framework for Understanding Hear…

San Diego Heart Failure Symposiums

P. Taub

Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists

Ezekiel Emanuel

How Are Outpatient irAEs Managed at Mass General

Cleveland Clinic Taussig Cancer Institute

K. Rubin

Carbohydrate-Insulin Model: A Physiological Perspective on the Obesi…

The Texas Heart Institute

D. Ludwig

Clinical Pearls on Obesity Dosing: Zepbound and Wegovy

Eduard Fatakhov

Ozempic, Zepbound, and More: Behavioral Interventions & Weight Loss …

Baystate Health

M. Gortakowski, K. Jobbins

Update on Obesity Pharmacotherapy

Brian Wojeck

Weight Wellness for the PCP: The Next Generation of Anti-Obesity Med…

University of Texas Southwestern Medical Center

J. Almandoz

Periendoscopic Management of Weight Loss and Diabetes Medications

New York Society of Gastroenterology and Endoscopy

S. Nagula